Broad Institute

OCTOBER 4, 2023

The molecule’s dual mechanism of action — targeting both tumor and immune cells — is unique compared to other cancer immunotherapies including PD-1 drugs, and the researchers think it could explain why the molecule was so effective on its own in animal models and may not even need to be used in combination with other drugs such as anti-PD-1 therapy.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

The Pharma Data

JANUARY 17, 2021

LONDON–( BUSINESS WIRE )– Ixaka Ltd , an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies (MCTs) and targeted nanoparticle (TNP) therapeutics.

Therapies 40

Therapies Clinical Trials Disease Immune Response 40

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JUNE 25, 2021

CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. The quality of the immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020. CHENGDU, China.–(

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

NOVEMBER 9, 2020

10, 2020 06:00 UTC. Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and they are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. PARIS & CAMBRIDGE, Mass.–(

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

NOVEMBER 22, 2020

23, 2020 10:10 UTC. Dr Hussam Shaheen, Director of Antibody Discovery and Engineering at Pandion Therapeutics, said: “Our TALON platform leverages natural immune regulatory mechanisms, to re-balance immune responses and ultimately advance discovery into novel treatments for autoimmune and inflammatory diseases.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

The Pharma Data

JANUARY 21, 2021

Precigen is focused on next-generation gene and cell therapy using precision technology. In January 2020, it raised $69 million in Series D, bringing the then-total up to $150 million. Pharvaris – Based in The Netherlands, Pharvaris is planning a $100 million Nasdaq IPO to raise money for its therapy for hereditary angioedema (HAE).

Immune Response 52

Immune Response Laboratories Trials Therapies 52

The Pharma Data

DECEMBER 10, 2020

11, 2020 02:48 UTC. The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

NOVEMBER 12, 2020

12, 2020 — Lung cancer patients who harbor certain bacteria in the airways may have a poorer prognosis, a new study finds, adding to evidence that the body’s “microbiome” may play a role in cancer patients’ outlook. © 2020 HealthDay. Posted: November 2020. THURSDAY, Nov. All rights reserved.

Immune Response 52

Immune Response Research Doctors Treatment 52

The Pharma Data

NOVEMBER 15, 2020

16, 2020 /PRNewswire/ — Cytiva , a global life sciences leader, is supporting Clover Biopharmaceuticals , a global clinical-stage biotechnology company, to help accelerate the development and manufacturing of a protein-based S-Trimer subunit vaccine candidate. SHANGHAI , Nov. About Cytiva.

Vaccine 52

Vaccine Immune Response Clinical Trials Science 52

The Pharma Data

DECEMBER 13, 2020

14, 2020 /PRNewswire/ — Synlogic, Inc. Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. Nature Communications 11, 2739 (2020)). CAMBRIDGE, Mass. ,

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

JANUARY 19, 2021

TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. In January 2020, it raised $69 million in Series D, bringing the then-total up to $150 million.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ 2020 Apr 9;72(9):1435–46. Arthritis Rheumatol.

Immune Response 52

Immune Response Trials Treatment Disease 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Adicet Bio, Inc. Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. T cell therapies by Adicet, and marks the beginning of clinical development of a deep pipeline of “off-the-shelf” ??

FDA 40

FDA Immune Response Clinical Trials Engineering 40

The Pharma Data

SEPTEMBER 9, 2020

producing CD8+ T cell responses, which is thought to promote an anti-viral effect. In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFN? billion doses by the end of 2021. Pfizer Disclosure Notice.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

DECEMBER 28, 2020

29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. . HOUSTON , Dec.

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

AUGUST 20, 2020

These results informed the selection of the BNT162b2 candidate for the pivotal Phase 2/3 global study in up to 30,000 participants that started in July 2020, which has to date enrolled more than 11,000 participants, including in areas with significant SARS-CoV-2 transmission. billion doses by the end of 2021. billion doses by the end of 2021.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 10:45 UTC. Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. KENILWORTH, N.J.–(

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer?BioNTech In December 2020, Pfizer announced that the U.S. The Pfizer?BioNTech

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. . PLYMOUTH MEETING, Pa. , Only 6 related Grade 1 adverse events in 5 subjects were observed, primarily mild injection site reactions (e.g.,

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

SEPTEMBER 9, 2020

The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval. Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

DECEMBER 11, 2020

Friday, December 11, 2020. Government to supply doses in 2020 & 2021. In July 2020, Pfizer and BioNTech announced an agreement with the HHS and the DoD to meet the U.S. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Vaccine 52

Vaccine Clinical Trials Trials Licensing 52

The Pharma Data

DECEMBER 27, 2020

28, 2020 13:00 UTC. NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021. CARLSBAD, Calif.–( –( BUSINESS WIRE )– Lineage Cell Therapeutics, Inc.

Therapies 40

Therapies Clinical Trials Production Treatment 40

The Pharma Data

NOVEMBER 10, 2020

We’re excited to be collaborating with Tiziana to support the development of a novel, oral therapy that could provide Crohn’s patients with another option in their repertoire of treatments to combat this devastating disease.”. Tiziana Life Sciences January 9, 2020 Press Release ( [link] ). Billion by 2025. Cited References: 1.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

JANUARY 31, 2021

While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. Curing HIV remains the ultimate aspiration for Gilead’s HIV research and development efforts.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

SEPTEMBER 5, 2021

Food and Drug Administration Breakthrough Therapy Designation was granted to tezepelumab in September 2018 for patients with severe asthma, without an eosinophilic phenotype. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

JANUARY 4, 2021

. chPD1 will be used in the Company’s proprietary chimeric antigen receptor therapy (CAR-T) platform using gamma-delta T-cells (GD-T). Barber’s work will give Kiromic a significant acceleration in the clinical development of its therapy platform and an even more significant advantage over its competitors.

Therapies 40

Therapies Molecular Biology Immune Response Science 40

The Pharma Data

DECEMBER 17, 2020

17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. If the therapy proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the U.S. , who require oxygen therapy due to COVID-19, OR. TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

MAY 7, 2021

under an Emergency Use Authorization (EUA) granted by the FDA on December 11, 2020. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The Pfizer-BioNTech COVID-19 Vaccine is currently available in the U.S.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

DECEMBER 21, 2020

21, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with tezepelumab compared to placebo. THOUSAND OAKS, Calif. , Reese , M.D.,

Trials 40

Trials Production Clinical Trials Therapies 40

The Pharma Data

FEBRUARY 18, 2022

Visit this page on BMS.com for more information on Bristol Myers Squibb’s scientific approach and resources on gastrointestinal immune-mediated diseases. Many patients have an inadequate response or do not respond at all to currently available therapies. About Ulcerative Colitis. It is estimated that approximately 12.6

Clinical Trials 40

Clinical Trials Treatment Immune Response Disease 40

The Pharma Data

NOVEMBER 9, 2020

9, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe asthma. THOUSAND OAKS, Calif. ,

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

DECEMBER 15, 2020

In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medical school. Daratumumab induced substantial clinical responses in the patients. The cells secrete auto-antibodies, but do not respond to standard immunosuppression.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. The Company expects topline data in the Phase 3 RELIEF study in the fourth quarter of 2020. solution), which is in Phase 2 development for the treatment of life-threatening cocaine intoxication and has FDA Breakthrough Therapy designation. CHATHAM, N.J.,

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

OCTOBER 20, 2020

21, 2020 /PRNewswire/ — Moleculin Biotech , Inc., ” The relevance of targeting lung localized tumors is that it could provide a means to address a significant unmet need in cancer therapy. . HOUSTON , Oct. We are hopeful we can submit this IND before year-end.”

Clinical Trials 40

Clinical Trials Pharmaceutical Companies Treatment Immune Response 40

The Pharma Data

JULY 21, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52